2 enrolling by invitation. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Enrolling by invitation 2 |
Follow cemiplimab: new trials by email Literature Review of cemiplimab trials Research Report on cemiplimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment Fianlimab+cemiplimab - Melanoma | Phase 2 | Enrolling by invitation | Regeneron Pharmaceuticals | 48 | 2025-04-14 | 2026-07-13 |
| International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone - Plasma Cell Myeloma | Phase 2 | Enrolling by invitation | Sanofi | 70 | 2023-04-05 | 2026-10-15 |
Melanoma (1) · Multiple Myeloma (1)
Regeneron Pharmaceuticals (1) · Sanofi (1)
United States (2) · Australia (1) · Brazil (1) · Chile (1) · China (1) · Czechia (1) · Finland (1) · France (1) · Greece (1) · Ireland (1) · Italy (1) · Japan (1) · New Zealand (1) · Russia (1) · South Korea (1)
2023 (1)